Association between hypermutator phenotype, clinical variables, mucoid phenotype, and antimicrobial resistance in Pseudomonas aeruginosa

Journal of Clinical Microbiology

Volumn 46, Issue 10, 2008, Pages 3491-3493

  Waine, David J ^a,b   Honeybourne, David ^a,b   Smith, E Grace ^b   Whitehouse, Joanna L ^b   Dowson, Chris G ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; GENE MUTATION; HUMAN; MALE; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ADULT; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MUTATION; POLYSACCHARIDES, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY FUNCTION TESTS; ROC CURVE;

PSEUDOMONAS AERUGINOSA;

EID: 53649108809     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00357-08     Document Type: Article

References (17)

1. Alkawash, M. A., J. S. Soothill, and N. L. Schiller. 2006. Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms. APMIS 114:131-138.
2. Andrews, J. M. 2006. BSAC standardized disc susceptibility testing method (version 5). J. Antimicrob. Chemother. 58:511-529.
3. Ciofu, O., B. Riis, T. Pressler, H. E. Poulsen, and N. Hoiby. 2005. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob. Agents Chemother. 49:2276-2282.
4. Cystic Fibrosis Foundation. 1996. Cystic fibrosis foundation registry: 1996 annual data report. Cystic Fibrosis Foundation, Bethesda, MD.
5. Cystic Fibrosis Trust Clinical Standards and Accreditation Group. 2001. Standards for the clinical care of children and adults with cystic fibrosis in the UK. Cystic Fibrosis Trust Clinical Standards and Accreditation Group, London, United Kingdom.
6. Foweraker, J. E., C. R. Laughton, D. F. Brown, and D. Bilton. 2005. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J. Antimicrob. Chemother. 55:921-927.
7. Hentzer, M., G. M. Teitzel, G. J. Balzer, A. Heydorn, S. Molin, M. Givskov, and M. R. Parsek. 2001. Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J. Bacteriol. 183:5395-5401.
8. Learn, D. B., E. P. Brestel, and S. Seetharama. 1987. Hypochlorite scavenging by Pseudomonas aeruginosa alginate. Infect. Immun. 55:1813-1818.
9. Leid, J. G., C. J. Willson, M. E. Shirtliff, D. J. Hassett, M. R. Parsek, and A. K. Jeffers. 2005. The exopolysaccharide alginate protects Pseudomonas aeruginosa biofilm bacteria from IFN-γ-mediated macrophage killing. J. Immunol. 175:7512-7518.
10. Li, Z., M. R. Kosorok, P. M. Farrell, A. Laxova, S. E. West, C. G. Green, J. Collins, M. J. Rock, and M. L. Splaingard. 2005. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 293:581-588.
11. Macia, M. D., D. Blanquer, B. Togores, J. Sauleda, J. L. Perez, and A. Oliver. 2005. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob. Agents Chemother. 49:3382-3386.
12. Macia, M. D., N. Borrell, J. L. Perez, and A. Oliver. 2004. Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion. Antimicrob. Agents Chemother. 48:2665-2672.
13. Macia, M. D., N. Borrell, M. Segura, C. Gomez, J. L. Perez, and A. Oliver. 2006. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:975-983.
14. Miles, A. A., S. S. Misra, and J. O. Irwin. 1938. The estimation of bactericidal power of blood. J. Hyg. 38:733-749.
15. Oliver, A., B. R. Levin, C. Juan, F. Baquero, and J. Blazquez. 2004. Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob. Agents Chemother. 48:4226-4233.
16. Oliver, A., R. Canton, P. Campo, F. Baquero, and J. Blazquez. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1254.
17. Taddei, F., M. Radman, J. Maynard-Smith, B. Toupance, P. H. Gouyon, and B. Godelle. 1997. Role of mutator alleles in adaptive evolution. Nature 387:700-702.